Foundry Therapeutics 1

Foundry Therapeutics 1 is a biotechnology company focused on the development of novel therapeutic candidates. The company was established as part of a collaboration between the venture capital firm Forbion and the contract research organization Charles River Laboratories. It operates within a virtual drug discovery framework, leveraging external expertise to advance early-stage programs toward clinical development. While specific therapeutic areas and targets remain undisclosed, the company is part of a broader 'Foundry' initiative designed to efficiently translate academic and internal research into viable drug candidates.